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Abstract
Background: Obesity-associated type 2 diabetes is rapidly increasing throughout the world. It is generally recognized that
natural products with a long history of safety can modulate obesity.
Aim: To investigate the development of obesity in response to a high fat diet (HFD) and to estimate the effect of L-carnitine
and an Egyptian Herbal mixture formulation (HMF) (consisting of T. chebula, Senae, rhubarb, black cumin, aniseed, fennel and
licorice) on bodyweight, food intake, lipid profiles, renal, hepatic, cardiac function markers, lipid Peroxidation, and the glucose
and insulin levels in blood and liver tissue in rats.
Method: White male albino rats weighing 80-90 gm, 60 days old. 10 rats were fed a normal basal diet (Cr), 30 rats fed a high-
fat diet (HFD) for 14 weeks during the entire study. Rats of the HFD group were equally divided into 3 subgroups each one
include 10 rats. The first group received HFD with no supplement (HFD), the 2nd group HFD+L-carnitine and the third group
received HFD+HMF. Carnitine and HMF were administered at 10th week (start time for treatments) for 4 weeks.
Body weight, lipid profile & renal function (urea, uric acid creatinine) ALT & AST activities, cardiac markers, (LDH, C.K-NAC
and MB) the oxidative stress marker reduced glutathione (GSH), and Malondialdehyde (MDA) catalase activity, in addition to
glucose, insulin, and insulin resistance in serum & tissues were analyzed.
Results: Data showed that feeding HFD diet significantly increased final body weight, triglycerides (TG), total cholesterol, &
LDL concentration compared with controls, while significantly decreasing HDL; meanwhile treatment with L-carnitine, or HMF
significantly normalized the lipid profile.
Serum ALT, urea, uric acid, creatinine, LDH, CK-NAC, CK-MB were significantly higher in the high fat group compared with
normal controls; and administration of L-carnitine or herbal extract significantly lessened the effect of the HFD. Hyperglycemia,
hyperinsulinemia, and high insulin resistance (IR) significantly increased in HFD in comparison with the control group. The
treatment with L-carnitine or HMF improved the condition. HFD elevated hepatic MDA and lipid peroxidation associated with
reduction in hepatic GSH and catalase activity; whereas administration of L-carnitine or herbal extract significantly ameliorated
these hepatic alterations.
Conclusion: HFD induced obesity associated with a disturbed lipid profile, defective antioxidant stability, and high values of IR
parameters; this may have implications for the progress of obesity related problems. Treatment with L-carnitine, or HMF extract
improved obesity and its associated metabolic problems in different degrees. Also HMF has antioxidant, hypolipidaemic insulin
sensitizing effects. Moreover HMF might be a safe combination on the organs whose functions were examined, as a way to
surmount the obesity state; and it has a distinct anti-obesity effect.
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Introduction
The global prevalence of obesity is increasing rapidly
among adults as well as among children and adolescents
in places where high dietary fat intake is a major risk factor
for the development of obesity [1]. Obesity is reaching
epidemic proportions worldwide; it is correlated with var-
ious comorbidities, among which the most relevant are
dyslipidemia [2], diabetes mellitus T2DM [3], fatty liver
(which can later progress to nonalcoholic fatty liver dis-
ease [4]), cardiovascular (CV) diseases such as heart fail-
ure (HF) and coronary heart disease (CHD) [5].
L-carnitine is essential for the transfer of long-chain fatty
acids from the cytosol to mitochondria for subsequent
beta oxidation. Its lack impairs the ability to use fat as fuel.
This can result in an acute metabolic decompensation,
most often early in life, with hepatic encephalopathy and
hypoketotic hypoglycemia [6].
Carnitine (L-beta-hydroxy-gamma-N,N,Ntrimethyl-ami-
nobutyric acid) is one of the "nutraceuticals" that has plei-
otropic biologic effects. L-carnitine administration to
carnitine-deficient rats led to normalization in myocardial
function including indices of contractility relaxation,
systolic diastolic blood pressure [7].
The liver is a central organ for carnitine metabolism;
therefore it is not surprising that carnitine metabolism is
impaired in patients and experimental animals with cer-
tain types of chronic liver disease. L-carnitine can have a
therapeutic role in some of these conditions [8].
Nowadays there is an increased demand for using plants
in therapy "back to nature" instead of using synthetic
drugs which may have adverse effects. Traditional medic-
inal plants are often cheaper, locally available, and easily
consumable (raw or as simple medicinal preparations).
These simple medicinal preparations often mediate bene-
ficial responses due to their active chemical constituents.
The reason for using herbs in combination is that herbs
have chemicals components which can bring strong
effects on body. When herbs are used in combination it
helps the body better manage potentially undesirable
effects of any one and each herb in the combination/for-
mulation plays a curative or pacifying role. It is therefore
preferable to use herbal combinations instead of depend-
ing on single herbs [9].
The HMF contains antioxidants, stimulant laxatives that
are present in T. chebula, senna, licorice and rhubarb. The
herbal supplement also includes carminatives which are
represented by black cumin, aniseed, fennel, and licorice
[10]. These carminative herbs are utilized to improve
digestion or to treat dyspepsia or irritable bowel symp-
toms of ulcerative colitis; and to treat maladies of specific
organs in the digestive system, such as the pancreas, liver,
stomach or large and small intestines.
Demulcents and carminatives are often used to soften and
physiologically balance the harsh effects of stimulant lax-
atives [11]. Both licorice and aniseed are considered to be
flavors that by altering the characteristics of the solute,
causing sweet and sour tanginess.
The ethanolic extract of roots of rhubarb led to the isola-
tion of anthraquinones: chrysophanol, physcion, emo-
din, glucopyranoside, stilbenes: desoxyrhaponticin,
rhaponticin, resveratrol, rhapontigenin, glucopyranoside,
ampelopsin B and rhaponticin [12].
The mechanism of rhubarb action is twofold: 1) stimula-
tion of colonic motility, which augments propulsion and
accelerates colonic transit which in turn reduces fluid
absorption from the fecal mass; 2) an increase in the para-
cellular permeability across the colonic mucosa, probably
owing to an inhibition of Na+/K+ exchanging ATPase or to
an inhibition of chloride channels. This results in an
increase in the water content in the large intestine. Purga-
tion is followed by an astringent effect owing to the tan-
nins presence [13].
Licorice root is the dried peeled or unpeeled root of Gly-
cyrrhiza glabra known as Spanish licorice; or of other vari-
eties of Glycyrrhiza glabra [14].
Constituents with antioxidant capacity were isolated from
Glycyrrhiza glabra. The isolated compounds were identi-
fied as the isoflavans, Hispaglabridin A, Hispaglabridin B,
Glabridin; the two chalcones, isoprenyl chalcone deriva-
tive isoliquiritigenin; theisoflavone, formononetin.
Among these compounds, Glabridin constituted the
major component in the crude extract and the most
potent antioxidant toward LDL oxidation [15].
Glycyrrhizin inhibited histamine release from rat mast
cells prevented carbon Tetrachloride-induced liver lesions
and macrophage-mediated cytotoxicity. Glycyrrhizin pro-
tected the liver apparently through its membrane stabili-
zation effects [16]. Glycyrrhizic acid its glucoside,
glycyrrhizin impart the unique licorice taste. Glycyrrhizin
is 50 times sweeter than sucrose. Licorice sweetness has a
slower onset than sugar so it is important for the palata-
bility of the HMF.
Aniseed is the dried ripe fruits of the Pimpenella anisum
family, containing licorice-like components, anise which
is sweet, very aromatic and anethole, are the principal
component of anise oil [17].Diabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
Page 3 of 14
(page number not for citation purposes)
Fennel is the ripe fruit, or seed, of Foeniculum vulgare. It
has a strongly aromatic odor somewhat bitter sweet pun-
gent taste. The British Herbal Pharmacopoeia reported its
action as a carminative is considered to be one of the best
additions to purgative medicines, and it is often com-
pounded with T. chebula, senna and rhubarb, in infusions
or mixture [18]. Fennel seed extracts may possess a radical
scavenging antioxidant activity due to the occurrence of
some phenol compounds in fennel being responsible for
such an activity [19].
Black cumin is the dried ripe seeds of Nigella sativa (NS),
strongly aromatic when crushed, reminiscent of anise or
nutmeg, also slightly bitter tasting at first, then spicy and
somewhat pungent. It contains fixed, volatile oils which
contain thymoquinone and several monoterpenes,
including p-cymene a-pinene [20]. Many therapeutic
effects of NS extracts have been documented, including
immunomodulative, anti-inflammatory, antitumor, anti-
diabetic and antiulcerogenic [21] effects in both clinical
and experimental studies.
Recently, the use of powerful drugs has become a popular
means to overcome excess weight. Adverse effects may
limit their overall usefulness. Accordingly, recent prelimi-
nary reports suggesting that herbs with along history of
use of other natural substances is less likely to produce
toxicity and might be effective in reducing food intake,
promoting significant weight loss, are encouraging. Pre-
liminary findings suggest that, at least, one formulation of
herbs has such promise.
However, the effect of HMF on lipid peroxidation and
antioxidant enzymes activities in obesity has not been
examined and so far, little is known on the medicinal val-
ues of HMF. Thus, the present investigation was carried
out in order to study the possible antiobesity, hypolipi-
demic, hypoglycemic and antioxidant effect of HMF. The
effect was compared with L-carnitine in a model of high
fat diet-induced obesity. Moreover, the extract was also
tested for its hepatic cardiac and renoprotective effects in
rats.
Material and Methods
This study was approved by the Committee of Scientific
Ethics at Beni Suef University
Materials
1- Diets
composition of the experimental diet (g/kg diet) was
according to the formula of Kim et al. [22]. It included the
normal diet for control rats (fat 5%, carbohydrates 65%,
proteins, 20.3% fiber 5%, salt mixture and 3.7% vitamin
mixture 1%). The high fat diet contained fat 46%, carbo-
hydrates 24%, proteins, 20.3%, fiber 5%, salt mixture
3.7%, vitamin mixture 1%. Normal and HFD constituents
were purchased from El-Gomhoria Company, Cairo,
Egypt. HFD was preserved at 4°C until used.
2- Experimental animals
40 white male albino rats weighing 80-90 gm, 60 day old
were used for this study. They were purchased from the
National Research Center, Cairo, Egypt. All animals were
housed in stainless steel cages contain barriers for each rat
for individual housing and the cage contain 6 rats and
each rat had a tag number. They kept under standard envi-
ronmentally controlled, clean-air room with temperature
24 ± 5°C, illumination (12 h light/12 h dark cycles), a rel-
ative humidity of 60 ± 4%, and water and rodent chow
were available ad libitum throughout the period of the
investigation. They were housed for two weeks after their
arrival in the laboratory for accommodation.
Our work was carried out in accordance with the guide-
lines of Faculty of Science at Beni Suef University for ani-
mal use. These animals were used for induction of obesity.
Food consumption was calculated daily at the same time
by subtracting the amount of food left over in each cage
barrier for each rat from the measured amount of food
provided at the previous day (gm/day/rat). The mean of
food consumption per each rat was considered by divid-
ing the amount of food eaten in a week by 7.
The average of food consumptions were represented in
gm/day/rat and the body weight for each rat was deter-
mined once a week (g).
3- Drug administration
L-carnitine (dietary supplement): 1 ml containing 250
mg carnitine was purchased from the Arab Company for
Pharmaceuticals Medicinal Plants (MEPACO, Egypt
(Enshas El Raml-Sharkeiya). Oral administration of a
dose of 250 mg/kg daily was done according to the
method described by Oka et al [23]. Handling of the ani-
mal was the same for all groups and did not affect weight
gain.
4- Plant material preparation of the herbal formulation
Herbs were purchased from local Mohey El-Attar Com-
pany in El-Minia  city. Identification and extractions of
medicinal plants were completed in department of Phar-
macognacy, faculty of pharmacy, El Minia University.
The preparation, composition dose of the herbal formula
of each herbal extract in the HMF and the identification of
their main chemical groups were realized as previously
described as follow: Rhubarb 750 mg/kg body weight
according to Kang Jin [24], senna (Cassia angustifolia) 750
mg/kg body weight [25], T. chebula 750 mg/kg bodyDiabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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weight [26], Sweet fennel 300 mg/kg body weight [11],
Aniseed 10 mg/kg body weight [27], licorice (Glycyrrhiza
galabra) 300 mg/kg body weight [15] Black cumin (Nig-
ella sativa) 300 mg/kg body weight [28].
The extraction was done by water extract for T. chebula,
ethanol for senna and Nigella sativa, ethanol-water extract
for rhubarb, licorice, Pimpenella anisum and Foeniculum
vulgare (fennel). The extract of each plant was collected
and the mixture administered orally as a suspension by
stomach tube at a dose of 790 mg/kg body weight daily,
the volume of the vehicle being kept constant at 1 ml/kg.
The identified compounds belonged to some specific
structural types: flavenoids glabridin, and sennosides.
After isolation by several column chromatographic steps
from the extract and characterization by spectroscopic
methods, the main compounds were identified as triterpe-
noids, coumarin, gallic acid, chebulin and ellagic acid as
well as other phenolic compounds from T. chebula extrac-
tion.
Anthraquinones, rhein, and tannins were isolated from
rhubarb extraction. Glabridin from Glycyrrhiza galabra
extraction, thymoquinone from Nigella sativa extraction.
Phenolic content, d-limonene β-myrcene from Foeniculum
vulgare (fennel) extraction and anethole form Pimpenella
anisum extract.
Methods
1-Experimental design and animal grouping
A total 40 rats were randomly assigned into two groups,
normal 10 rats and obese 30 rats. Obesity was induced in
rats for 70 day by feeding the high fat diet. The rats were
included in four groups after induction of obesity. In the
experiment 10 rats were used in each group.
￿ Normal group, 10 rats fed on normal diet during the
entire study (98 day).
￿ Obese group, 10 rats given high-fat diet during the
entire study (98 day) and saline oral daily by using stom-
ach tube at 10th week.
￿ HFD+carnitine group, 10 obese rats received HFD dur-
ing the entire study and 250 mg/kg L-carnitine for 28 days
as a single daily dose in the morning.
￿ HFD+ HMF group, 10 obese rats received HFD during
the entire study and 790 mg/kg mixed herbal extract for
28 days as single oral daily by using stomach tube.
Our goal is to achieve obesity model in 10 weeks follow-
ing by treatment period for 4 weeks. This model provided
us reliable method and resembles the clinical cases of
obesity and its treatments; also this period of treatment is
safe and recommended in previous research.
2- Sampling and tissue preparation
Blood Sampling
By the end of the experimental periods, venous blood
samples were collected from the orbital sinus of normal,
obese control, obese treated rats via glass capillaries at
fasting state. The blood samples were collected in dry glass
centrifuge tubes, allowed to coagulate at room tempera-
ture and centrifuged at 3500 rpm for 15 minutes at room
temperature for separation of serum.
The clear, non-haemolysed supernatant sera were sepa-
rated using clean dry disposable plastic syringes and
stored at -20°C for subsequent biochemical measure-
ments as follows: lipid profile, liver enzyme activities
related to its function, kidney function, heart biomarkers,
glucose, insulin concentration, and oxidative stress mark-
ers.
Tissue samples
Rats were sacrificed by decapitation and an abdominal
incision was immediately done for separation of hepatic,
perirenal, and visceral adipose tissues. These were dried
on filter paper and weighed (g.). The liver was immedi-
ately excised and weighed (g.) and underwent homogeni-
zation for GSH & MDA catalase measurements.
3- Biochemical analysis of Serum and tissue
Serum glucose was estimated according to the method of
Trinder [29] using Stanbio Laboratory USA Kits. Serum
insulin was assayed in the Radioactive Isotopes Unit, Cen-
tral Department of Scientific Analysis and Testing,
National Research Center (Dokki, Giza) using radioim-
munoassay kits (Diagnostic Products Corporation, Los
Angeles, USA) [Coat-A-Count] according to the method of
Marschner et al. [30]. Insulin resistance was calculated
using the Homeostasis Model Assessment [31]. ALT and
AST activities were measured according to the method of
Reitman et al., [32] using kits purchased from Rox Com-
pany, United Kingdom.
Serum urea and creatinine levels were measured colori-
metrically [33]; serum uric acid was measured according
to the method of Sanders et al.[34] using kits purchased
from Diamond Diagnostic Egypt. Serum was analyzed for
total cholesterol [35], triglycerides [36], VLDL [37], and
HDL [38], by enzymatic colorimetric methods using kits.
Serum was evaluated for CK-MB [39] CK-NAC and LDH
activity [40]. Liver lipid peroxidation was measured
through Malondealdehyde (MDA) levels, according to the
methods of Mihara and Uchiyama [41]. Liver glutathione
content and catalase (CAT) activity was determinedDiabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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according to the procedure of Beutler et al. [42] and
Cohen et al. [43] respectively.
Statistical analysis
Statistical analysis was carried out using Graph Pad Instat
software (version 3, ISS-Rome, Italy). Unless otherwise
specified, groups of data were compared with an unpaired
t-test one-way analysis of variance (ANOVA) followed by
Tukey-Kramer (TK) multiple comparisons post-test. Val-
ues of P < 0.05 were regarded as significant. Data were
expressed in tables and figures as mean ± standard error
(SEM).
Results
Body weight increased significantly in rats on the HFD
compared with controls (Figure 1), while treatments with
L-carnitine or HMF significantly reduced this gain during
the treatment period (Table 1 and figure 2).
Food consumption increased significantly in the HFD
group compared with controls (Figure 3), while treat-
ments with L-carnitine or HMF significantly ameliorated
the changes during the treatment period (Table 2 and fig-
ure 4).
Serum TG, cholesterol, LDL/VLDL levels, and perirenal
and mesenteric fat were significantly elevated in the HFD
group, while HDL was significantly decreased compared
to the controls. Additional administration of L-carnitine
or HMF significantly improved these changes (Table 3).
Serum LDH, CK, AST, ALT, urea, uric acid, and creatinine
concentrations were significantly higher in the HFD group
compared to the control one; these changes, were affected
by supplementation with L-carnitine and HMF (Table 4).
Serum levels of glucose, insulin and hepatic MDA, were
significantly raised, while hepatic GSH and catalase were
significantly lowered in the HFD group compared to the
controls. These alterations were ameliorated by adminis-
Effect of normal and HFD on whole body weights weekly  during 10 weeks in rats Figure 1
Effect of normal and HFD on whole body weights 
weekly during 10 weeks in rats. Body weight increased 
significantly in rats fed on the HFD during 5th, 7th, 9th and 10th 
W. compared with controls. Values significantly different 
compared to normal *P < 0.05.
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Effect of HFD, L-carnitine and HMF on body weights during  treatment period in rats Figure 2
Effect of HFD, L-carnitine and HMF on body weights 
during treatment period in rats. Treatments with L-car-
nitine or HMF significantly reduced the elevated body weight 
during the treatment period compared to HFD. (HFD vs. L 
carnitine or HMF) Means not sharing common letter are sig-
nificantly different (p < 0.05).
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Table 1: Effect of HFD, L-Carnitine and HMF on whole body 
weights of rats.
Weeks HFD L. carnitine HMF
11th Week 255.0 ± 3.54a 231.2 ± 2.56b 222.8 ± 3.58b
12th Week 270.0 ± 2.60a 247.0 ± 3.36b 239.6 ± 4.19b
13th Week 282.6 ± 2.09a 261.0 ± 3.81b 256.4 ± 5.07b
14th Week 286.4 ± 3.97a 250.0 ± 3.41b 262.0 ± 6.04b
Values significantly different compared to normal P** < 0.01. Values 
are expressed as means ± SEM. Means not sharing common letter are 
significantly different (p < 0.05).Diabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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tration of L-carnitine HMF but there were no differences
between L-carnitine and HMF (Table 5).
Discussion
Effect of diet treatments on body weight food 
consumption
Obesity is considered to be a disorder of energy balance,
occurring when energy expenditure is no longer in equi-
librium with daily energy intake, so as to ensure body
weight homeostasis [44]. Although the etiology of obesity
is complex, dietary factors, particularly the consumption
of a HFD, is considered a risk factor for its development
[45].
The current results showed that body weight increased sig-
nificantly in the HFD group compared with the normal
group (Figure 1), a result in accordance with that of Xu et
al [46]; this is associated with increased food intake.
Consumption of the HFD led to obesity because it facili-
tates the development of a positive energy balance leading
to an increase in visceral fat deposition; this led to abdom-
inal obesity in particular. Moreover, Schrauwen-Hinder-
ling et al [47] found that HFD feeding is accompanied by
molecular adaptations that favor fat storage in muscle
rather than oxidation.
In the current study, rats fed HFD consumed considerably
more food than the control rats throughout the experi-
ment (Table 2 and Figure 3). So their caloric intake was
increased and they showed a large increase in perirenal
visceral adipose tissue mass (Table 3), suggesting that the
excess energy led to the build up of adiposity. This is the
source of the increase in body weight. Rat consuming the
high fat ration actually received about 27% more kilocal-
ories, more weight, and had larger fat pads than rats fed
only chow. Rats consuming a palatable dietary fat in addi-
tion to a standard chow diet take in about 10% more cal-
ories a day than rats fed only the chow diet and over time,
Effect of normal and HFD on food consumption during 10  weeks in gm/day/rat Figure 3
Effect of normal and HFD on food consumption dur-
ing 10 weeks in gm/day/rat. Food consumption increased 
significantly in the HFD group during 7th, 9th and 10th W. 
compared with controls. Values significantly different com-
pared to normal *P < 0.05.
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Effect of HFD, L-carnitine and HMF on food consumption  during treatment period gm/day/rat Figure 4
Effect of HFD, L-carnitine and HMF on food con-
sumption during treatment period gm/day/rat. Treat-
ments with L-carnitine or HMF significantly ameliorated the 
changes during 13th and 14th W. of the treatment period 
(HFD vs. L carnitine or HMF). Means having different letter 
are significantly different (p < 0.05).
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Table 2: Effect of HFD, L-Carnitine and HMF on food intake in 
rats
Weeks HFD L. carnitine HMF
11th Week 17.33 ± 1.05a 16 ± 1.58a 15.63 ± 0.62a
12 stWeek 20 ± 1.58a 17.50 ± 1.32a 15 ± 0.71a
13th Week 24 ± 2.27a 20 ± 1.63b 17 ± 1.23b
14th Week 24.75 ± 2.29a 22 ± 1.83a, b 20 ± 1.47b
Values significantly different compared to normal P** < 0.01. Values 
are expressed as means ± SEM. Means not sharing common letter are 
significantly different (p < 0.05).Diabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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become obese and exhibit a number of complications of
obesity.
Our results showed a significant decrease in food intake,
whole body weight, and adipose tissue accumulation
from oral administration of L-carnitine (Tables 1, 2).
Interest in the role of L-carnitine as a feed additive to
improve whole body composition arose from the desire to
partition nutrients away from lipid accretion, causing
improvement of nitrogen balance; L-carnitine also attenu-
ated visceral fat accumulation and accelerated the normal-
ization of food intake [48].
The current results due to the effect of HMF, showed a sig-
nificant decrease in body weight and food consumption
(Table 1, 2) in accordance with the findings of York et al
[49]. Several isoflavans constituents of licorice are unique
phytoestrogens, which like estradiol, affect the serotoner-
gic system, inhibiting serotonin re-uptake and thereby
increasing the levels of serotonin in synaptic clefts. This
enhances satiety and resembles the action of sibutramine,
but naturally [50].
Dietary phytoestrogens may also activate AMPK leading to
a reduction in food intake [51]. Our study is a novel trial
for using a phytoestrogen in fennel, licorice and anise as a
Table 3: Effect of HFD, L-Carnitine and HMF on plasma lipid profile and adipose tissues weight in HFD rats
Normal diet HFD L-Carnitine HMF
TG (mg/dl) 63.94 ± 2.19 172.6 ± 1.73**a 118.5 ± 1.21 b 116 ± 1.83b
VLDL (mg/dl) 12.79 ± 0.44 34.52 ± 0.35**a 23.69 ± 0.24b 23.20 ± 0.37b
T.C (mg/dl) 95.29 ± 1.03 152.7 ± 2.56**a 109.6 ± 1.51b 113.1 ± 1.54b
HDL (mg/dl) 70.97 ± 1.89 53.34 ± 2.52**a 67.45 ± 1.4b 65.59 ± 1.36b
LDL (mg/dl) 12.48 ± 2.0 67.06 ± 1.65**a 17.29 ± 0. 85b 17.42 ± 2.08b
Visceral fat (gm) 3.54 ± 0.51 14.8 ± 1.07**a 10.10 ± 0.33b 10.40 ± 0.93b
Perirenal fat (gm) 3.54 ± 0.51 14.8 ± 1.07**a 10.10 ± 0.33 b 10.40 ± 0.93b
Values significantly different compared to normal P** < 0.01. Values are expressed as means ± SEM. Means not sharing common letter are 
significantly different (p < 0.05)
Table 4: Effect of HFD, L-Carnitine and HMF on cardiac biomarkers, liver enzyme activity and kidney function tests of HFD rats
Normal diet HFD L-Carnitine HMF
LDH
(u/I)
258.5 ± 10.8 541.7 ± 10.62**a 472.8 ± 6.4b, c 497.9 ± 8.23b
C.K-NAC
(u/I)
250.2 ± 12.6 457.7 ± 10.58**a 407.4 ± 8.9b 396.4 ± 8.92b, c
C.K-MB (u/I) 130.0 ± 5.03 262.0 ± 9.55**a 213.8 ± 3054b 209.8 ± 8.95b
AST (u/I) 24.94 ± 0.95 56.8 ± 1.09**a 41.18 ± 1.11b 44.24 ± 1.09b
ALT (u/I) 17.14 ± 0. 93 5.37 ± 0.95**a 24.60 ± 0.69b 25.67 ± 0.95b
Urea (mg/dl) 36.60 ± 0.94 50.11 ± 1.33**a 40.86 ± 0.71b, d 42.36 ± 0.72b
Uric acid (mg/dl) 2.33 ± 0.07 5.92 ± 0.08**a 4.94 ± 0.07b 5.13 ± 0.05b
Creatinine (mg/dl) 0.59 ± 0.05 1.31 ± 0.06**a 0.96 ± 0.02b 1.01 ± 0.03c
Values significantly different compared to normal P** < 0.01. Values are expressed as means ± SEM. Means not sharing common letter are 
significantly different (p < 0.05).Diabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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natural serotonin reuptake inhibitor instead of sibu-
tramine.
Anetholein fennel as a carminative herb improves the
digestion by stabilization of the gastrointestinal mucous
membrane and causing the pancreas to increase its secre-
tions [11]. Hydroxyl-anthracene glucosides, especially
sennosides A B in senna and T. chebula of HMF improve
gastrointestinal motility and influence colonic motility
thereby reducing fluid absorption and facilitate weight
loss.
Effect of diet treatments on serum lipid profile in rats
In the present study, a high fat diet resulted in dyslipi-
demic changes as illustrated by increasing triglycerides,
VLDL, total cholesterol and low density lipoprotein LDL
and a decrease in serum level of high density lipoprotein
HDL (Table 3) a finding in accordance with that of Woo
et al. [52].
L-carnitine supplementation produced significant
decreases in serum TG, VLDL, and T-cholesterol, LDL-C
while there were significant increases in HDL cholesterol
in obese rats. These results are in agreement with those of
González-Ortiz et al. [53] and El-Metwally et al., [54]
who reported that oral L-carnitine increases plasma free
carnitine levels, improves dyslipidemia and decreases oxi-
dative stress, with reduction of cardiac parameters.
L-carnitine administration to obese rats reduces signifi-
cantly serum hypertriglyceridemia (Table 3) via decreased
synthesis of triglycerides by the liver or by inhibition of
triglyceride release from the liver. Also L-carnitine induced
marked reductions in total serum cholesterol in skeletal
muscles of obese rats [55].
L-carnitine is necessary for mitochondrial transport
metabolism of long-chain fatty acids, thus for myocardial
energetic metabolism. Fatty acids cross mitochondrial
membranes as acyl-carnitine derivatives to enter pathways
for oxidation, acylation, chain shortening or chain elon-
gation-desaturation. Therefore, L-carnitine-dependent
fatty acid transfer is central to lipid metabolism; dietary
supplementation of L-carnitine improves the utilization
of fat providing marked reduction in plasma levels of TG
[56].
In our experimental rat model of obesity, treatment with
HMF led to significant decrease in TG, VLDL, T-choles-
terol and LDL-C but a significant increase in HDL choles-
terol (Table 3), a result in agreement with that of Murali
et al [57].
T. chebula components of HMF have hypocholestero-
lemic activity that might be mediated through increased
cholesterol excretion in the feces. In addition anthraqui-
none glycosides from rhubarb in the HMF have lipid-low-
ering effects, resulting in depression of lipid
accumulation. It consequently has anti-atherosclerotic
properties [58].
Glycyrrhizin, the active constituent in licorice root, which
is another plant in the mixture, exerts hypocholestero-
lemic action by stimulating the conversion of cholesterol
into bile acids without effect on cholesterol synthesis [59].
Another herbal supplement in the HMF, Nigella sativa,
contains active constituents, phytosterols (mostly b-sito-
sterol, stigmasterol campesterol) with the ability to reduce
the intestinal absorption of diet biliary cholesterol [60].
Table 5: Effect of diet and treatments on serum glucose, insulin, insulin resistance lipid peroxidation in obese rats
Normal diet HFD L-Carnitine HMF
Glucose (mg/dl) 57.87 ± 1.96 145.1 ± 2.26**a 120.9 ± 1.96b, c 118.0 ± 3.23c, d
Insulin
(μIU/ml)
4.40 ± 0.15 6.69 ± 0.13**a 4.5 ± 0.07b 4.41 ± 0.04b
Insulin resistance 1.17 ± 0.09 2.89 ± 0.07**a 2.46 ± 0.09b 2.40 ± 0.05b
M.D.A (n mol M.D.A/g/hr) 4.69 ± 0.06 9.72 ± 0.08**a 7.96 ± 0.08b, c 8.21 ± 0.07b
GSH (n mol/
100 mg tissue)
72.65 ± 0.72 57.31 ± 0.72**a 68.77 ± 0.89b, c 68.45 ± 0.46b
Catalase (K×10-2) 52.60 ± 0.96 19.88 ± 0.63**a 36.97 ± 0.71b 32.22 ± 1.06c
Values significantly different compared to normal P** < 0.01. Values are expressed as means ± SEM. Means not sharing common letter are 
significantly different (p < 0.05).Diabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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Effect of diet treatments on cardiac biomarkers in rats
The obese rats showed a significant increase in the activity
of serum LDH, CK-NAC and CK-MB when compared to
the normal rats (Table 4). Similar results were reported by
Diniz et al. [61]. Reduced muscle mitochondrial content
function with increasing obesity would lower the total cel-
lular ATP yield, which would result most notably in
increased mitochondrial volume, and increased glycolytic
enzymes necessitating increased activity of creatine
kinase, as this enzyme is responsible for rapidly transfer-
ring high-energy phosphate groups from the site of pro-
duction to the site of use [62].
The increased blood levels of total cholesterol, LDL, VLDL
as well as lowered levels of HDL in HFD rat have been
identified in the development of hypercholestremia,
which is one of the risk factors for CAD [63]. Administra-
tion of L-carnitine produces a significant decrease in the
activity of CK-NAC, CK-MB and LDH (Table 4). This is in
agreement with Ferrari et al. [64], who reported a reduc-
tion in cardiac markers, with L-carnitine having a good
protective effect on myocardium.
In conclusion, L-carnitine stimulates the activity of pyru-
vate dehydrogenase (PDH) which is an important enzyme
catalyzing the rate-limiting step in lactate utilization. In
type 2 diabetes this led to significant decrease in the activ-
ity of LDH [65]. Moreover, L-carnitine in the β-oxidation
of fatty acid as parallel source for energy acts synergisti-
cally with the creatine/phosphocreatine/creatine kinase
system to produce significantly decreased activity of crea-
tine kinase.
This effect is mainly attributable to the vasodilatation
property of L-carnitine, which both improves energetic
metabolism of the hypoxic/damaged muscle and
enhances wash-out of algogenic metabolites.
Our findings showed that obese rats treated with the HMF
exhibited significant decreases in LDH, CK-NAC and CK-
MB activity (Table 4), in with the findings of Suchalatha
et al. [66], who reported that T. chebula extract treatment
ameliorates the effect of lipid peroxide formation that is
related to the activities of diagnostic myocardial marker
enzymes.
The rhubarb content in our mixture could prevent the
development of atherosclerosis through regulating vascu-
lar inflammatory processes in rats fed with an atherogenic
diet [67]; and the thymoquinone content in N. sativa nor-
malized cardiac histopathology, as it decreased lipid per-
oxidation [20,21].
Effect of treatments on renal function tests of HFD in rat
The obese rats showed a highly significant increase in the
concentration of serum urea, uric acid creatinine, com-
pared with the normal group (Table 4) which is in agree-
ment with the results of Cindik et al. [68].
Abnormal renal function is mainly associated with dia-
betic nephropathy. The pathophysiology involves glucose
that binds irreversibly to proteins in the kidney circulation
to form advanced glycosylation end products that can
form complexes that contribute to renal damage by stim-
ulation of fibrotic growth factors [69].
HFD induces alteration of renal lipid metabolism by an
imbalance between lipogenesis and lipolysis in the kid-
ney, as well as systemic metabolic abnormalities and sub-
sequent renal lipid accumulation leading to renal injury
[70]. There is an association between CKD and insulin
resistance that contributes to increased VLDL production
and decreased HDL levels, both of which are considered
risk factors for the development of kidney dysfunction
and markers for progression of CKD [71].
In addition HFD resulted in hyperinsulinemia, activation
of the renin-angiotensin system, glomerular hyperfiltra-
tion and structural changes in the kidney that may be the
precursors of more severe glomerular injury associated
with prolonged obesity [72].
The oral administration of L-carnitine (Table 4) shows
that serum concentration of urea, uric acid and creatinine
were highly significantly decreased. The effect of L-carni-
tine on renal lipid metabolism could serve as a new ther-
apeutic approach, as it counters the renal changes
associated with metabolic syndrome [73]. Hence, L-carni-
tine has beneficial effects on renal function.
Although there is still debate on the significance of uric
acid as a risk factor for cardiovascular disease, many phy-
sicians do consider elevated uric acid to be a component
of the metabolic syndrome. There is little support for an
independent causal role for serum uric acid in the devel-
opment of CHD. However, uric acid may provide useful
prognostic information in subjects with hypertensive vas-
cular disease, suggesting that the influence of uric acid on
CHD is explained by the secondary association of it with
other risk factors such as dyslipidemia, hyperinsulinaemia
and obesity [74].
The oral administration of HMF extract (Table 4) clarified
that serum concentration of urea; uric acid and creatinine
were significantly decreased. Rhubarb results in lowering
the serum creatinine level causing decrease in urinary pro-
tein excretion, attenuation of lipid derangements,
decreased oxygen consumption and the hypertrophy ofDiabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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the remnant kidney [75]. Rhein, another ingredient in
rhubarb of HMF, improves cell metabolism through glu-
cose transporter-1: it decreases cell hypertrophy, indicat-
ing that there are multiple active ingredients even in a
single herbal medicine involved in the multiple therapeu-
tic effects of rhubarb in CKD, and suggesting that HMF
might delay the progression of renal failure.
The herbal drugs containing tannins have a uremic-toxin-
decreasing action, whereas rhubarb's tannins significantly
improved BUN creatinine, glomerular filtration rate and
renal blood flow [76]. In this respect rhubarb has proven
effective as a diuretic in rabbit models, apparently by
blocking sodium-potassium ATPase in the renal medulla
[77].
The HMF therapy retains the balance between lipogenesis
and lipolysis in the kidney to counteract the obesity-asso-
ciated renal damage, in addition to maintaining cellular
hydration due to laxative effect of senna, which is associ-
ated with diuretic effect of rhubarb, collectively leading to
improvement in renal blood flow and consequent
improvement in kidney function.
Effect of treatments on glucose and insulin of HFD rats
Our results showed that a high fat diet results in signifi-
cant increase in serum glucose, insulin level and insulin
resistance (Table 5), which parallels the results obtained
from Zhang et al. [78]. Diminished hepatic and muscular
uptake of glucose produced hyperlipidemia due to
increased fat mobilization from adipose tissue and resist-
ance to the antilipolytic actions of insulin. Impaired insu-
lin action is associated with an oversupply of lipids. This
increased availability led to either elevated lipid stored in
insulin target tissues (e.g. muscle, liver adipose) or
increased plasma FFA or triglyceride [79].
The weight loss in this study due to oral administration of
L-carnitine is associated with hypoglycemia, as it pro-
motes insulin sensitivity, thus lowering insulin resistance
in obese rats, possibly by regulating the cell energy metab-
olism or reducing free fatty acids as shown also by
González-Ortiz et al. [53] and [55].
Obesity is associated with endothelial dysfunction
through direct mechanisms, as insulin resistance in asso-
ciation with diabetes mellitus and dyslipidemia, indi-
rectly, by the production of adipokines and pro-
inflammatory cytokines, induces oxidative stress that
affect the role of endothelium in modulating vascular
function structure [80].
Our findings (Table 5) indicated a significant decrease of
serum glucose, insulin and its resistance in obese rats
treated with extracts of HMF. Some prenylflavonoids,
such as glycycoumarin, glycyrin, dehydroglyasperin C and
dehydroglyasperin D, in licorice ethanolic extract, are
effective in preventing and ameliorating diabetes, abdom-
inal obesity and preventing hypertension and metabolic
syndrome [81].
In addition, hypoglycemia induced by T. chebula is prob-
ably mediated through enhanced secretion of insulin
from the beta-cells of the pancreatic islets or through an
extra pancreatic mechanism. Moreover, T. chebula may
reduce the effect of inflammatory cytokine release during
diabetes which may be one of the causative agents for the
insulin resistance [69].
The hypoglycemic action of thymoquinone due to Nigella
sativa in HMF could be partly due to preservation of β-cell
integrity of the pancreatic islets causing a significant
increase in insulin secretion. It also sensitized hepatocytes
to the action of insulin. Furthermore, NS treatment exerts
a therapeutic protective effect on diabetes by decreasing
oxidative stress, preserving pancreatic beta-cell integrity
[21].
Effect of treatments on hepatic enzymes and lipid 
peroxidation in HFD-rats
The current data showed a significant increase in the activ-
ity of enzymes AST and ALT in the obese compared with
normal rats (Table 4). Liver is bombarded by the free fatty
acids (FFA) that pour out of the adipose tissue into the
portal blood. This can directly cause inflammation within
the liver cells, which then release further pro-inflamma-
tory cytokines, leading to more hepatocyte injury and
affecting the integrity of liver cells [82].
Administration of L-carnitine produces a significant low-
ering effect in the activity of AST and ALT in obese rats, a
result in agreement with Yapar et al. [83]. Improvement
of hepatocyte integrity does not seem to be limited to its
obligatory role in the transmembrane import of fatty acids
for mitochondrial β-oxidation, but L-carnitine prevents
lipotrope methyl group wastage and increased production
of polyamines with known immunomodulatory proper-
ties. Additionally L-carnitine can directly modify cytokine
responses and reduce TNF-production. Moreover, lipid
peroxidation is significantly blunted by oral administra-
tion of L-carnitine [84].
The present results demonstrate that the mixture of HMF
showed a significant decrease in the activity of both AST
and ALT (Table 4) agreeing with the resulted obtained by
Celik and Isik [19].
D-limonene and β-myrcene in fennel (Foeniculum vulgare)
has a potent hepatoprotective action; D-limonene
increases the concentration of liver GSH which is requiredDiabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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by several enzymes that participate in the formation of the
correct disulfide bonds of many proteins. Polypeptide
hormones participate in the metabolism of xenobiotics.
β-myrcene elevates the levels of apoproteins CYP2B1
CYP2B2, which are subtypes of P450 enzyme system that
catalyse the oxidative metabolism of a wide variety of
exogenous chemicals including drugs, toxins, and endog-
enous compounds such as fatty acids [85]. Nigella sativa
and licorice root extract of HMF possesses hepatoprotec-
tive effects in some models of liver toxicity [86].
HFD generates oxidative stress in obese rats as shown by a
marked increase in the levels of MDA and a distinct dimi-
nution in hepatic GSH, as well as activities of the antioxi-
dant enzyme catalase. All showed reduced activity in
hyperlipidemic rats (Table 5).
Hyperglycemia in the HFD group activates different path-
ways leading to increased oxidative stress. Increased activ-
ity of the polylol pathway inhibition of the pentose
phosphate pathway as a result of hyperglycemia resulted
in decreased intracellular levels of NADPH, which is
required for regeneration of GSH from its oxidized form
GSSG [87]. The net result was non-enzymatic disruption
of H2O2  and increased levels of cellular superoxides,
hydroperoxides, hydroxyl radicals as well as other radi-
cals.
In addition oxidative stress may be increased in metabolic
syndrome due to dyslipidemia resulting from increased
levels of FFA and TGs that led to increased formation of
foam cells, rendering LDL less dense and more vulnerable
to oxidation and uptake by macrophages [88].
Our results indicated that L-carnitine produced a signifi-
cant inhibition of MDA production and a significant
increase in GSH and activity of catalase (Table 5). L-carni-
tine reduces significantly the content of thiobarbituric
acid reactive substances (TBARS), and causes marked
increase in activity of catalase in skeletal muscles of obese
rats [55]. Moreover L-carnitine favorably modulates oxi-
dative stress causing a reduction in oxidized LDL choles-
terol levels [89].
L-carnitine effectively protects and improves mitochon-
drial function in vivo: it acts as an antioxidant, so by
inhibiting ROS it protects the vascular endothelial tissues
against oxidative damage in hypertension [90]. Thus, L-
carnitine treatment effectively protected the liver tissue
against oxidative damage and showed marked improve-
ment in its antioxidant status.
The current results demonstrated an antioxidative effect of
HMF, as indicated by increased GSH level and hepatic cat-
alase activity in comparison with obese rats (Table 5).
Administration of aqueous extract of T. chebula effectively
modulated oxidative stress and enhanced antioxidant sta-
tus in the liver [91], which may be due to the total
polyphenol content, expressed as gallic acid. T. chebula
extract has the potential to play a role in the prevention of
oxidative damage in living systems which can be attrib-
uted to its membrane stabilizing activities [92]. It has
stronger antioxidant activity than α-tocopherol, due to the
presence of hydroxybenzoic acid derivatives, flavonol
aglycones and their glycosides.
Glabridin, a natural polyphenolic isoflavone antioxidant
from licorice root extract in HMF possesses potent free
radical scavenging activity that could promote a decrease
in lipid peroxidation and could protect LDL from oxida-
tion [93]. This would occur via a direct interaction with
the lipoprotein and/or an indirect effect through accumu-
lation in arterial macrophages. Therefore licorice repre-
sents a potent nutrient, which can attenuate the
development of atherosclerosis, secondary to its antioxi-
dant properties against lipids peroxidation in arterial cells
[94].
Polyphenols, the main compound of N. sativa oil in HMF,
have many biological properties. They possess powerful
antioxidative components, which can inhibit membrane
lipid peroxidation [28], and their administration exerts a
therapeutic protective effect by decreasing oxidative stress.
Foeniculum vulgare extract, another constituent of the
HMF, has potent antioxidant activity, as has been docu-
mented with various antioxidant assays. These activities
include total antioxidant, free radical scavenging, super-
oxide anion radical scavenging, and hydrogen peroxide
scavenging [95]. Antioxidant activity of the anthraqui-
nones of rhubarb in the HMF may help protect against
lipid peroxidation and free radical damage; its extracts
will probably be useful for the development of safe food
additives [12].
This study showed the antioxidant effect of dietary supple-
ment represented by L-carnitine and free radical scavenger
activities of herbal supplements represented by T.
chebula, licorice, fennel, aniseed and Nigella sativa extract
in the HMF.
Based on these broad observations, we suggest that high
fat diet-induced obesity resulted in deleterious effects in
kidney and liver tissues. HMF extract or carnitine supple-
mentation counteracted the injuries, and ameliorated or
normalized most the biochemical parameters.
Collectively obesity is associated with cardiometabolic
complications, including insulin resistance, dyslipidemia,
cardiovascular disease (CVD). When comparing therapiesDiabetology & Metabolic Syndrome 2009, 1:17 http://www.dmsjournal.com/content/1/1/17
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for obesity, both L-carnitine and HMF have shown
improvements in body weight, lipid profile, glucose lev-
els, liver, and kidney and cardiac marker of function, as
well as insulin resistance and oxidative stress markers.
It can be concluded that in this study HFD induced a
model of obesity associated with high body weight,
hyperlipaemia, hyperinsulinemia, insulin resistance,
hepatic oxidative stress, associated hepatic, cardiac renal
function marker disturbance in rats. The obesity and its
associated problems in this study could be ameliorated in
different degrees by using L-carnitine or HMF extract.
The study also showed that herbal extract mixture signifi-
cantly improved body weight, cholesterol, LDL triglycer-
ide concentrations, creatinine, urea, ALT, oxidative stress,
resulting from the high-fat diet. So it also had hypolipi-
demic, renoprotective, hapatoprotective, antioxidant and
antiobesity effect.
It could be helpful to use HMF in conjunction with drugs;
herbal extract might be a safer combination to surmount
the overweight state. Positive results from such trials
would confirm the medicinal usefulness of empirical
combinations of traditional Egyptian medicines.
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